Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 1/2022

13.02.2021 | Original Article

Discrepancies in post-ST-elevation myocardial infarction care in women compared with men: evaluating for implicit bias—a single-centre study

verfasst von: Stephanie Whittle, Helene Angerer, Manuja Premaratne, Viviane Khalil

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent research has demonstrated discrepancies in care post-ST-elevation myocardial infarction (STEMI), showing that women often have delays in time to percutaneous coronary intervention (PCI) and are less often prescribed evidence-based medications for secondary prevention. This single-centre study evaluated gender differences in management and local prescribing patterns of STEMI patients on discharge consistent with implicit bias, benchmarked against Australian clinical guidelines.

Method and Result

A retrospective, consecutive study of 318 patients admitted with a STEMI was conducted at a large tertiary hospital from January 2018 until October 2019. Data was collected from medical records including patient demographics, door-to-balloon (DTB) time, and pharmacological management. The mean age of women with a STEMI was higher (67.90 years in women; 64.17 in men, p = 0.013). DTB times were unaffected by gender with 88% of both men and women receiving PCI in less than 90 min (1.04 95% CI (0.44-2.46). Women were less likely to be prescribed an angiotensin-converting enzyme (ACE)-inhibitor/angiotensin receptor blocker (ARB) on discharge (p = 0.003). However, all other medications prescribed were appropriate between genders based on recommended guidelines.

Conclusions

 Our study identified excellent adherence with recommended guidelines, challenging recent data both internationally and from the Victorian Cardiac Outcomes Registry (VCOR). Pharmacological and revascularisation management post-STEMI for both male and female patients was equal, suggesting implicit bias is not universal and may be institutional. Health services should evaluate their practices to identify sources of implicit bias, which may influence their management of women presenting with a STEMI.
Literatur
2.
Zurück zum Zitat Radovanovic D, Erne P, Urban P et al (2007) Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20 290 patients from the AMIS Plus Registry. Heart 93(11):1369–1375CrossRef Radovanovic D, Erne P, Urban P et al (2007) Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20 290 patients from the AMIS Plus Registry. Heart 93(11):1369–1375CrossRef
3.
Zurück zum Zitat Akhter N, Milford-Beland S, Roe MT et al (2009) Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J 157(1):141–148CrossRef Akhter N, Milford-Beland S, Roe MT et al (2009) Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J 157(1):141–148CrossRef
4.
Zurück zum Zitat Leurent G, Garlantézec R, Auffret V et al (2014) Gender differences in presentation, management and inhospital outcome in patients with ST-segment elevation myocardial infarction: data from 5000 patients included in the ORBI prospective French regional registry. Arch Cardiovasc Dis 107(5):291–298CrossRef Leurent G, Garlantézec R, Auffret V et al (2014) Gender differences in presentation, management and inhospital outcome in patients with ST-segment elevation myocardial infarction: data from 5000 patients included in the ORBI prospective French regional registry. Arch Cardiovasc Dis 107(5):291–298CrossRef
5.
Zurück zum Zitat Khan E, Brieger D, Amerena J et al (2018) Differences in management and outcomes for men and women with STelevation myocardial infarction. Med J Aust 209(3):118–123CrossRef Khan E, Brieger D, Amerena J et al (2018) Differences in management and outcomes for men and women with ST­elevation myocardial infarction. Med J Aust 209(3):118–123CrossRef
6.
Zurück zum Zitat Chapman EN, Kaatz A, Carnes M (2013) Physicians and implicit bias: how doctors may unwittingly perpetuate health care disparities. J Gen Intern Med 28:1504–1510CrossRef Chapman EN, Kaatz A, Carnes M (2013) Physicians and implicit bias: how doctors may unwittingly perpetuate health care disparities. J Gen Intern Med 28:1504–1510CrossRef
7.
Zurück zum Zitat Stehli J, Martin C, Brennan A et al (2019) Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coronary intervention. J Am Heart Assoc 8:e012161CrossRef Stehli J, Martin C, Brennan A et al (2019) Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coronary intervention. J Am Heart Assoc 8:e012161CrossRef
8.
Zurück zum Zitat Chew DP, Scott IA, Cullen L et al (2016) National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart Lung Circ 25(9):895–951CrossRef Chew DP, Scott IA, Cullen L et al (2016) National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart Lung Circ 25(9):895–951CrossRef
9.
Zurück zum Zitat Hwang C, Levis JT (2014) ECG diagnosis: ST-elevation myocardial infarction. Perm J 18(2):e133CrossRef Hwang C, Levis JT (2014) ECG diagnosis: ST-elevation myocardial infarction. Perm J 18(2):e133CrossRef
10.
Zurück zum Zitat Radovanovic D, Seifert B, Urban P et al (2014) Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart 100:288–294CrossRef Radovanovic D, Seifert B, Urban P et al (2014) Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart 100:288–294CrossRef
11.
Zurück zum Zitat IBM Corp (2017) IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp IBM Corp (2017) IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp
Metadaten
Titel
Discrepancies in post-ST-elevation myocardial infarction care in women compared with men: evaluating for implicit bias—a single-centre study
verfasst von
Stephanie Whittle
Helene Angerer
Manuja Premaratne
Viviane Khalil
Publikationsdatum
13.02.2021
Verlag
Springer International Publishing
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 1/2022
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-021-02528-z

Weitere Artikel der Ausgabe 1/2022

Irish Journal of Medical Science (1971 -) 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.